ORETON (methyltestosterone) by Merck & Co. is clinical pharmacology estrogens: endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. First approved in 1979.
Drug data last refreshed 21h ago
CLINICAL PHARMACOLOGY Estrogens: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the…
Worked on ORETON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.